Paxlovid rebounds more common than first thought, doctors say; FDA rejects Brainstorm Cell Therapeutics’ ALS application; Faze Medicines is shutting down.
Five things for pharma marketers to know: Thursday, November 10, 2022
Clovis Oncology faces potential bankruptcy; FDA advisory committee supports AstraZeneca’s 2-in-1 asthma inhaler for adults; Two teaspoons of lab-made blood could help people with rare blood conditions.
Five things for pharma marketers to know: Wednesday, November 9, 2022
China deals with violent protests against COVID restrictions; Softbank-backed Hexagon Bio raises more than $100 million for fungi mining; Generic drugmakers beat appeal in Zantac lawsuit.
Five things for pharma marketers to know: Monday, November 7, 2022
New Omicron subvariants emerge in the U.S. as COVID-19 deaths remain high; Bayer drops antisense therapy fesmersen; GSK says antibiotic appears to be effective against urinary tract infections.
Five things for pharma marketers to know: Friday, November 4, 2022
Rubius Therapeutics lays off 82% of its workforce; Wegovy helped teens lose weight; ‘Considerable’ monkeypox transmission happens before symptoms, study finds.
Five things for pharma marketers to know: Thursday, November 3, 2022
Vertex’s nonaddictive painkiller candidate shows promise as an alternative to opioids; New cancer drug prices rise 53% since 2017; Unity Biotechnology’s diabetic macular edema drug to move into pivotal study next year.
Five things for pharma marketers to know: Wednesday, November 2, 2022
J&J decides to halt Phase I clinical trial of Essa Pharma’s prostate cancer drug; U.S. could have first RSV vaccine by 2023 season; Lebanon receives first cholera vaccines from France.
Five things for pharma marketers to know: Monday, October 31, 2022
Flu hospitalizations are up significantly and earlier than usual; Senate report concludes that SARS-CoV-2 came from ‘a research-related incident’; Lecanemab may have contributed to a patient’s death in June.
Five things for pharma marketers to know: Friday, October 28, 2022
FDA orders recall of blood pressure medication due to cancer risk; GSK drops regulatory plan for arthritis drug amid failed tests; Eli Lilly commits $92.5 million to Purdue for pharma scholarships.